BioWorld

May 15, 2008

View Archived Issues

Amarin Adds $28M to Support CNS, Cardiovascular Pipeline

Amarin Corp. plc, which rebounded from dismal Huntington's disease data with the December acquisition of Ester Neurosciences Ltd., is moving full steam ahead once again, thanks to a $28 million cash infusion. (BioWorld Today) Read More

Wall Street Analysts Prepare for ASCO Flood Starting Friday

Read More

ApoD: Is it Toxic, Or a Life-Extender?

Read More

Lawmakers Debate FDA Liability Preemption Rules

Read More

FDA Places Hold on Geron's Cell Therapy, CEO 'Disappointed'

Read More

Other News To Note

Read More

U.S. Patent Disclosures

Read More

Clinic Roundup

Read More

Earnings Roundup

Read More